Non-small cell lung cancer · line 2 · Capmatinib monotherapy (GEOMETRY mono-1) — MET ex14 NSCLC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-CAPMATINIB-NSCLC |
| ID | IND-NSCLC-2L-MET-EX14-CAPMATINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-GEOMETRY-WOLF-2020 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track for MET ex14 NSCLC any line (1L or 2L+). Tepotinib (separate Indication) is once- daily alternative.
Used By
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L
Indication
IND-NSCLC-2L-MET-AMP-CAPMATINIB- IND-NSCLC-2L-MET-AMP-CAPMATINIB